{"disease":{"id":"schistosomiasis-haematobium","name":"schistosomiasis haematobium"},"drugs":{"marketed":[{"drug_id":"cysticide","indication_name":"Schistosomiasis due to S. Haematobium","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cysticide","company_name":"Merck KGaA, Darmstadt, Germany","drug_phase":"phase_1","molecular_target":"Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05658614","title":"Anti-Schistosomiasis Sm14-vaccine in Senegal","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Oswaldo Cruz Foundation","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}